A Phase 3 interventional study of Dupilumab and Matching Placebo in Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals. Completed at 27 sites in 2 countries. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing dupilumab in Eosinophilic Esophagitis — 4 open to participants now, 7 under way, 1 of them phase 3. dupilumab · Eosinophilic Esophagitis.
Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 3, and was the 3rd registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →4 of the 11 studies testing dupilumab in Eosinophilic Esophagitis are open now, in 1 country. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 6 mo–6 yrs
University of Colorado, Denver · Sites in United States
Ages 12–25
University of California, San Diego · Sites in United States
Ages 22+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 1 Year to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 47 across the 11 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 7 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 7 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria.
The Secondary objectives are:
This is a 3-part study:
Key Inclusion Criteria:
Key Exclusion Criteria:
Key Exclusion for Patients Re-Entering the Study (for Entry into Part C, as defined in protocol):
NOTE: Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
Drug: Dupilumab · Drug: Matching Placebo
Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight
Drug: Dupilumab · Drug: Matching Placebo
Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
Drug: Dupilumab · Drug: Matching Placebo
Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight
Drug: Dupilumab · Drug: Matching Placebo
Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.
Drug: Dupilumab
Single-use, prefilled syringe
Also known as: •DUPIXENT, •REGN668, •SAR231893
Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
Time frame: At Week 16
Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
Time frame: At Week 16
Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available. Least squared (LS) mean and standard error (SE) from analysis of covariance (ANCOVA) model with Baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
Time frame: Baseline, Week 16
Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.
Time frame: Baseline, Week 16
Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.
Time frame: Baseline, Week 16
Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at Week 16 relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have a minimum/maximum score.
Time frame: Baseline, Week 16
Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
Time frame: Baseline, Week 16
Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16
The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.
Time frame: Baseline, Week 16
Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years)
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
Time frame: Baseline, Week 16
Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS mean SE derived from ANCOVA model.
Time frame: Week 16
Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
Time frame: Baseline, Week 16
Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 16
The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
Time frame: Baseline, Week 16
Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)
The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. The PESQ-P score was calculated based on the daily responses over a 14-day period (i.e., the 14 days prior to the baseline visit and the week 16 visit). The score ranges from 0 to 1. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS Mean SE from ANCOVA.
Time frame: Week 16
Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16
The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
Time frame: Baseline, Week 16
Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16
The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants. Values after first rescue treatment use were set to missing (censoring). WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the MI approach was used for the missing data due to other reasons. LS mean SE from ANCOVA model.
Time frame: Baseline, Week 16
Part A: Concentration of Functional Dupilumab in Serum at Baseline, Week 4 and 16
Concentration of functional dupilumab in serum at Baseline, Week 4 and 16 was reported in this outcome measure.
Time frame: Baseline, Week 4 and 16
Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
Time frame: At Week 52
Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
Time frame: At Week 52
Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
Time frame: Baseline, Week 52
Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.
Time frame: Baseline, Week 52
Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.
Time frame: Baseline, Week 52
Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52
The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores possibly ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.
Time frame: Baseline, Week 52
Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.
Time frame: Baseline, Week 52
Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years)
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.
Time frame: Week 52
Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary.
Time frame: Baseline, Week 52
Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52
The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
Time frame: Baseline, Week 52
Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years)
The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food.
Time frame: Week 52
Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52
The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
Time frame: Baseline, Week 52
Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
Time frame: Baseline, Week 52
Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at post-baseline relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
Time frame: Baseline, Week 52
Part B: Change From Baseline in Body Weight for Age Percentile at Week 52
Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.
Time frame: Baseline, Week 52
Part B: Change From Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52
BMI for age z-score indicates how much higher or lower a participant's BMI for age is relative to a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]). A z-score of "0" represents the population mean. An increase in the mean change in BMI for age z-score (ie, increase in the standard deviation \[SD\] from the reference growth chart) indicates an increase in BMI for age relative to the reference.
Time frame: Baseline, Week 52
Part B: Change From Baseline in Weight for Age Z-score at Week 52
Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.
Time frame: Baseline, Week 52
Part B: Change From Baseline in Body Weight From Height Z-score at Week 52
Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.
Time frame: Baseline, Week 52
Part B: Concentration of Functional Dupilumab in Serum at Week 32 and 52
Concentration of functional dupilumab in serum at Week 32 and 52 was reported in this outcome measure.
Time frame: Week 32 and 52
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
Time frame: From Baseline up to Week 16 in Part A
Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Adverse Events of Special Interest (AESIs) and TEAEs Leading to Permanent Discontinuation of Study Drug
An AE was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
Time frame: From Week 16 up to Week 52 in Part B
Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response
Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.
Time frame: From Baseline up to Week 16 in Part A
Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) by Maximum Titer Category
Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.
Time frame: From Baseline up to Week 16 in Part A
Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer
Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000. No participant exhibited a treatment-emergent ADA response in Part B and titer was not reported.
Time frame: From Week 16 up to Week 52 in Part B
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 100
Time frame: At Week 100
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 160
Time frame: At Week 160
Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 100
Time frame: Baseline to Week 100
Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 160
Time frame: Baseline to Week 160
Part C: Absolute Change in Mean EoE-HSS From Baseline to Week 100
Time frame: Baseline to Week 100
Part C: Absolute Change in Mean EoE-HSS From Baseline to Week 160
Time frame: Baseline to Week 160
Part C: Absolute Change in EoE-EREFS From Baseline to Week 100
Time frame: Baseline to Week 100
Part C: Absolute Change in EoE-EREFS From Baseline to Week 160
Time frame: Baseline to Week 160
Part C: Change in Total Score as Measured by the PEESSv2.0- Caregiver Version Questionnaire From Baseline to Week 100
The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants.
Time frame: Baseline to Week 100
Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 100
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
Time frame: Baseline to Week 100
Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 160
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
Time frame: Baseline to Week 160
Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature Baseline to Week 100
Time frame: Baseline to Week 100
Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature From Baseline to Week 160
Time frame: Baseline to Week 160
Part C: Change in Body Weight for Age Percentile From Baseline up to Week 100
Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.
Time frame: Baseline up to Week 100
Part C: Change in Body Mass Index for Age Z-score From Baseline up to Week 100
Difference in the 100-week change from baseline in BMI-for-age Z-score. BMI-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.
Time frame: Baseline up to Week 100
Part C: Change in Weight for Age Z-score From Baseline up to Week 100
Difference in the 100-week change from baseline in weight-for-age Z-score. Weight-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.
Time frame: Baseline up to Week 100
Part C: Change in Weight for Age Z-score From Baseline up to Week 160
Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.
Time frame: Baseline up to Week 160
Part C: Change in Weight for Height Z-score From Baseline up to Week 100
Difference in the 100-week change from baseline in Weight for height Z-score. Weight for height Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.
Time frame: Baseline up to Week 100
Part C: Change in Weight for Height Z-score From Baseline up to Week 160
Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.
Time frame: Baseline up to Week 160
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 100
Time frame: At Week 100
Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 160
Time frame: At Week 160
Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 100
Time frame: Baseline up to Week 100
Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 160
Time frame: Baseline up to Week 160
Part C: Number of Participants With TEAEs
Time frame: Up to Week 152
Part C: Number of Participants With Treatment-emergent SAEs
Time frame: Up to Week 152
Part C: Number of Participants With Treatment-emergent AESIs
Time frame: Up to Week 152
Part C: Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Treatment
Time frame: Up to Week 152
Part C: Number of Participants With Treatment-emergent ADA Responses
Time frame: From Week 52 up to Week 152
Part C: Concentration of Functional Dupilumab in Serum at Week 100
Time frame: At Week 100
| Milestone | Part A: Pooled Placebo (Placebo) | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose | Part C: Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Started | 34 | 31 | 37 | 0 | 0 | 0 | 0 | 0 |
| Completed | 33 | 29 | 37 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Pooled Placebo (Placebo) | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose | Part C: Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 14 | 18 | 29 | 37 | 0 |
| Completed | 0 | 0 | 0 | 14 | 18 | 29 | 36 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Part A: Pooled Placebo (Placebo) | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose | Part C: Dupilumab |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 |
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
| percentage of participants | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | 2.9 (0.07 to 15.33) | 67.6 (50.21 to 81.99) | 58.1 (39.08 to 75.45) |
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
| percentage of participants | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 16 | 2.9 (0.07 to 15.33) | 83.8 (67.99 to 93.81) | 67.7 (48.63 to 83.32) |
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available. Least squared (LS) mean and standard error (SE) from analysis of covariance (ANCOVA) model with Baseline measurement as covariate and the treatment, baseline weight group strata as fixed factors.
| percent change | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 16 | 20.98 ± 12.23 | -86.09 ± 11.84 | -77.93 ± 12.89 |
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.
| Score on a scale | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 16 | 0.023 ± 0.0498 | -0.879 ± 0.0481 | -0.757 ± 0.0524 |
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.
| Score on a scale | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 16 | 0.048 ± 0.0482 | -0.835 ± 0.0466 | -0.721 ± 0.0507 |
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at Week 16 relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have a minimum/maximum score.
| Score on a scale | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 16 | 0.34 (-1.84 to 1.65) | -1.895 (-2.03 to -1.61) | -1.930 (-2.00 to -1.39) |
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at Week 16 relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
| Score on a scale | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Eosinophilic Esophagitis (EoE) Diagnostic Panel (EDP) at Week 16 | 0.180 (-2.53 to 2.39) | -2.630 (-2.85 to -2.25) | -2.710 (-2.84 to -0.80) |
The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.
| score on a scale | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 16 | 0.3 ± 0.45 | -3.5 ± 0.42 | -3.0 ± 0.48 |
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
| proportion of days | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs as Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 16 (for Participants Aged ≥1 to <12 Years) | -0.17 ± 0.054 | -0.28 ± 0.052 | -0.18 ± 0.060 |
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measures the signs of EoE observed by the caregiver, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS mean SE derived from ANCOVA model.
| sign-free days | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Number of Sign-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years) | 8.93 ± 0.756 | 10.38 ± 0.735 | 8.93 ± 0.840 |
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
| proportion of segments | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 16 | -0.11 ± 0.032 | -0.16 ± 0.031 | -0.09 ± 0.036 |
The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
| proportion of days | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 16 | -0.26 ± 0.068 | -0.13 ± 0.077 | -0.16 ± 0.067 |
The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food. The PESQ-P score was calculated based on the daily responses over a 14-day period (i.e., the 14 days prior to the baseline visit and the week 16 visit). The score ranges from 0 to 1. WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the multiple imputations approach was used for the missing data due to other reasons. LS Mean SE from ANCOVA.
| sign-free days | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Number of Symptom-free Days During the 14-day Period Preceding Week 16 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) | 10.49 ± 0.953 | 8.69 ± 1.081 | 9.13 ± 0.936 |
The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
| proportion of segments | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 16 | -0.15 ± 0.040 | -0.08 ± 0.045 | -0.08 ± 0.039 |
The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants. Values after first rescue treatment use were set to missing (censoring). WOCF approach was used for imputing the missing data due to rescue treatment/AE/lack of efficacy, and the MI approach was used for the missing data due to other reasons. LS mean SE from ANCOVA model.
| score on a scale | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Change From Baseline in Total Score as Measured by the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) Version 2.0 Caregiver Version (PEESSv2.0-C) at Week 16 | -11.83 ± 2.909 | -19.86 ± 2.577 | -10.10 ± 2.785 |
Concentration of functional dupilumab in serum at Baseline, Week 4 and 16 was reported in this outcome measure.
| milligrams per liter (mg/L) | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|
| Baseline | 0 ± 0 | 0 ± 0 |
| Week 4 | 75.7 ± 25.7 | 40.6 ± 11.2 |
| Week 16 | 163 ± 60.8 | 86.0 ± 29.2 |
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
| percentage of participants | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils/High Power Field at Week 52 | 92.9 | 52.9 | 65.5 | 62.9 |
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
| percentage of participants | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eosinophils/High Power Field at Week 52 | 92.9 | 64.7 | 69.0 | 85.7 |
Peak esophageal intraepithelial eosinophil count was measured from esophageal biopsies. A total of at least 9 mucosal pinch biopsies were collected from 3 esophageal regions: 3 proximal, 3 mid, and 3 distal. The peak esophageal intraepithelial eosinophil count at each visit was the maximum of the quantities of eosinophils in the most inflamed hpfs across the 3 regions. If the quantity of eosinophils was missing for 1 or 2 esophageal regions, the peak eosinophil count was the maximum of the quantities of eosinophils from the region(s) where eosinophil quantities were available.
| percent change | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count at Week 52 | -92.72 ± 19.229 | -76.83 ± 41.228 | -85.41 ± 22.851 | -90.97 ± 14.482 |
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean grade scores summed over the 3 regions was the final score used in primary analysis, the mean grade score ranged from 0 to 3, with higher score indicating more severe.
| Score on a scale | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Grade Score at Week 52 | -0.804 ± 0.3099 | -0.885 ± 0.2962 | -0.773 ± 0.3374 | -0.967 ± 0.3920 |
EoE-HSS is a validated histologic scoring system that measures other histological abnormalities in addition to density of eosinophilic infiltration. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Higher total score indicated greater severity \& extent of histological abnormalities. For each of 3 esophageal regions (proximal, mid, and distal), the ratio of the sum of assigned score for each evaluated feature divided by maximum possible score (maximum value is 24) was calculated. The mean stage scores summed over the 3 regions was the final score used in primary analysis, the mean stage score ranged from 0 to 3, with higher score indicating more severe.
| Score on a scale | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in Mean Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) Stage Score at Week 52 | -0.767 ± 0.3114 | -0.855 ± 0.3485 | -0.784 ± 0.3183 | -0.892 ± 0.3181 |
The EoE-EREFS is a validated endoscopic scoring system for inflammatory and remodeling features of EoE including edema, rings, exudates, furrows, and stricture. The score was assessed in the proximal and distal esophageal regions with each region scored from 0 to 9 with total scores possibly ranging from 0 to 18. Higher scores indicate worse endoscopic inflammatory and remodeling findings.
| score on a scale | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52 | -5.82 ± 1.722 | -3.64 ± 3.342 | -4.50 ± 3.203 | -4.77 ± 3.081 |
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.
| proportion of days | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs Measured by Pediatric EoE Sign/Symptom Questionnaire - Caregiver Version (PESQ-C) at Week 52 | -0.20 ± 0.373 | -0.47 ± 0.395 | -0.49 ± 0.339 | -0.30 ± 0.299 |
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study.
| sign-free days | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Number of Sign-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-C (for Participants Aged ≥1 to <12 Years) | 11.58 ± 3.968 | 12.10 ± 4.652 | 11.35 ± 3.947 | 12.13 ± 4.053 |
PESQ-C is a novel, observer-reported outcome measure intended to be completed independently by caregivers of all pediatric EoE participants in the study. The PESQ-C measured the occurrence of signs of EoE and was completed once daily via an electronic diary.
| proportion of segments | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-C at Week 52 | -0.03 ± 0.249 | -0.24 ± 0.221 | -0.26 ± 0.250 | -0.17 ± 0.187 |
The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measured occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the proportion of days with 1 or more EoE symptoms.
| proportion of days | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in the Proportion of Days With 1 or More EoE Signs by Pediatric EoE Sign/Symptom Questionnaire - Participant Version (PESQ-P) (for Participants Aged ≥8 to <12 Years) at Week 52 | -0.33 ± 0.322 | -0.43 ± 0.369 | -0.42 ± 0.400 | -0.26 ± 0.396 |
The PESQ-P was a participant-reported outcome measure intended to be completed independently by participants ≥8 to \<12 years of age. The PESQ-P measures the signs of EoE, including stomach pain, heartburn, acid reflux, regurgitation, vomiting, food refusal, and trouble swallowing food.
| sign-free days | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Number of Symptom-free Days During the 14-day Period Preceding Week 52 as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) | 9.33 ± 8.083 | 11.67 ± 5.715 | 10.64 ± 4.943 | 13.63 ± 0.874 |
The PESQ-P was a participant-reported outcome measure intended to be completed independently by EoE participants ≥8 to \<12 years of age. The PESQ-P measured the occurrence of signs of EoE and was completed once daily via an electronic diary. Data from a 14-day period preceding the baseline visit and a 14-day period preceding week 16 will be used to calculate the total time segments within a day (night, morning, afternoon, evening) with 1 or more EoE symptoms.
| proportion of segments | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in the Proportion of Total Segments Within a Day (Night, Morning, Afternoon, Evening) With 1 or More EoE Signs as Measured by the PESQ-P (for Participants Aged ≥8 to <12 Years) at Week 52 | -0.17 ± 0.164 | -0.26 ± 0.269 | -0.21 ± 0.293 | -0.16 ± 0.284 |
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
| Score on a scale | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 52 | -2.715 (-2.755 to -2.505) | -2.615 (-2.810 to -2.430) | -2.625 (-2.775 to -2.550) | -2.670 (-2.710 to -2.530) |
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for T2INF reflect the expression at post-baseline relative to Baseline of the pre-specified gene set as a way to evaluate normalization of type 2 inflammation with treatment. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
| Score on a scale | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Normalized Enrichment Score (NES) for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 52 | -1.960 (-2.000 to -1.895) | -1.965 (-1.995 to -1.765) | -1.920 (-1.965 to -1.865) | -1.920 (-1.930 to -1.850) |
Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.
| Percentile | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in Body Weight for Age Percentile at Week 52 | -0.02 ± 13.893 | 5.48 ± 12.644 | 4.75 ± 11.968 | 5.96 ± 11.519 |
BMI for age z-score indicates how much higher or lower a participant's BMI for age is relative to a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]). A z-score of "0" represents the population mean. An increase in the mean change in BMI for age z-score (ie, increase in the standard deviation \[SD\] from the reference growth chart) indicates an increase in BMI for age relative to the reference.
| z-score | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in Body Mass Index (BMI) for Age Z-score for Participants ≥2 Years of Age at Week 52 | -0.0206 ± 0.54625 | 0.0687 ± 0.47605 | -0.0549 ± 0.88582 | 0.0987 ± 0.72329 |
Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.
| z-score | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in Weight for Age Z-score at Week 52 | 0.0640 ± 0.46264 | 0.2016 ± 0.39446 | 0.1445 ± 0.40310 | 0.2049 ± 0.40305 |
Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). A z-score of "0" represents the population mean. An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.
| z-score | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Change From Baseline in Body Weight From Height Z-score at Week 52 | 0.0962 ± 0.48902 | -0.0100 ± 0.51706 | -0.2700 ± 1.04895 | -0.0151 ± 0.67968 |
Concentration of functional dupilumab in serum at Week 32 and 52 was reported in this outcome measure.
| mg/L | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Week 32 | 105 ± 49.8 | 142 ± 48.5 | 99.0 ± 42.8 | 186 ± 59.5 |
| Week 52 | 101 ± 44.3 | 149 ± 59.1 | 83.0 ± 33.2 | 179 ± 75.3 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
| Participants | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Participants with any TEAE | 31 | 27 | 26 |
| Participants with any Serious TEAE | 0 | 2 | 1 |
| Participants with any AESI | 1 | 2 | 1 |
| Participants with any TEAE leading to permanent discontinuation of study drug | 2 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation patient administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or a medically important event. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
| Participants | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Participants with any TEAE | 14 | 15 | 28 | 34 |
| Participants with any Serious TEAE | 1 | 0 | 3 | 2 |
| Participants with any AESI | 0 | 1 | 3 | 4 |
| Participants with any TEAE leading to permanent discontinuation of study drug | 0 | 0 | 0 | 1 |
Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.
| Participants | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Part A: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response | 1 | 1 | 0 |
Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000.
| Participants | Part A: Pooled Placebo | Part A: Dupilumab High Dose | Part A: Dupilumab Low Dose |
|---|---|---|---|
| Treatment-emergent ADA Titer: Low | 1 | 1 | 0 |
| Treatment-emergent ADA Titer: Moderate | 0 | 0 | 0 |
| Treatment-emergent ADA Titer: High | 0 | 0 | 0 |
Treatment-emergent ADA was defined as a negative result or missing result at baseline with at least one positive post baseline result in the ADA assay. Samples positive in the dupilumab ADA assay were characterized for ADA titers (low, moderate and high). The low treatment-emergent ADA titer as defined as titer level \<1000, moderate as 1000 to 10000 and high as \>10000. No participant exhibited a treatment-emergent ADA response in Part B and titer was not reported.
| Participants | Part B: Placebo to Dupilumab Low Dose | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose |
|---|---|---|---|---|
| Part B: Number of Participants With Positive Treatment-emergent Antidrug Antibodies (ADA) Response and Titer | 0 | 0 | 0 | 0 |
| Percentage of participants | Part C: Dupilumab |
|---|---|
| Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf At Week 100 | 92.7 |
No measurements were reported for this outcome.
| Percentage of change | Part C: Dupilumab |
|---|---|
| Part C: Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) From Baseline to Week 100 | -91.50 ± 13.348 |
No measurements were reported for this outcome.
| Score on a scale | Part C: Dupilumab |
|---|---|
| EoE-HSS Grade Score | -0.851 ± 0.3909 |
| EoE-HSS Stage Score | -0.850 ± 0.3648 |
No measurements were reported for this outcome.
| Score on a scale | Part C: Dupilumab |
|---|---|
| Part C: Absolute Change in EoE-EREFS From Baseline to Week 100 | -5.34 ± 2.535 |
No measurements were reported for this outcome.
The PEESSv2.0-C is a caregiver-reported outcome measure that assesses the frequency and severity of EoE symptoms among pediatric participants. The PEESSv2.0-C consists of 20 items and has a one-month recall period. Each item had a 0-4 scale, which was transformed to 0-100 as follows: 0 = 0, 1 = 25, 2 = 50, 3 = 75, 4 = 100. The mean total PEESSv2.0 score was computed as the sum of all the item scores over the number of items answered. The total PEESSv2.0-C score ranges from 0 to 100 where higher scores indicate greater symptom burden among pediatric EoE participants.
| Score on a scale | Part C: Dupilumab |
|---|---|
| Part C: Change in Total Score as Measured by the PEESSv2.0- Caregiver Version Questionnaire From Baseline to Week 100 | -25.03 ± 21.867 |
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
| Score on a scale | Part C: Dupilumab |
|---|---|
| Part C: NES for the Relative Change in the EDP Transcriptome Signature From Baseline to Week 100 | -2.720 (-2.800 to -2.510) |
A Normalized Enrichment Score (NES) is a way to generate a single numerical value to represent a complex gene expression signature. Changes in NES score represented the overall changes in the expression of that molecular phenotype. The NESs calculated for the EDP reflect the expression at post-baseline relative to Baseline of a gene set that is differentially expressed between esophageal biopsies from EoE participants compared to healthy controls as a way to evaluate normalization of the molecular pathology. For each subject, an NES of 0 indicates no change from baseline, a negative score shows a reduction in disease score (more like normal) and positive score shows worsening (more active disease). NES does not have minimum/maximum score.
No measurements were reported for this outcome.
| Score on a scale | Part C: Dupilumab |
|---|---|
| Part C: NES for the Relative Change in the Type 2 Inflammation Transcriptome Signature Baseline to Week 100 | -1.970 (-2.000 to -1.900) |
No measurements were reported for this outcome.
Body weight for age percentile was calculated based on the growth charts from the Centers for Disease Control and Prevention (CDC) for ages 0 to 20 years (for ages 2 to \<12 years) and World Health Organization (WHO) growth charts for ages 0 to \<2 years (for ages 1 to \<2 years). These charts included a set of smoothed percentiles along with CDC LMS (Lambda-Mu-Sigma) parameters to allow the calculation of percentiles.
| Percentile | Part C: Dupilumab |
|---|---|
| Part C: Change in Body Weight for Age Percentile From Baseline up to Week 100 | 10.63 ± 18.227 |
Difference in the 100-week change from baseline in BMI-for-age Z-score. BMI-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.
| z-score | Part C: Dupilumab |
|---|---|
| Part C: Change in Body Mass Index for Age Z-score From Baseline up to Week 100 | 0.2009 ± 0.67389 |
Difference in the 100-week change from baseline in weight-for-age Z-score. Weight-for-age Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.
| z-score | Part C: Dupilumab |
|---|---|
| Part C: Change in Weight for Age Z-score From Baseline up to Week 100 | 0.3376 ± 0.59272 |
Weight for age z-score indicates how much higher or lower a participant's weight for age is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and World Health Organization (WHO) growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for age z-score (increase in the SD from the reference growth chart) indicates an increase in weight for age relative to the reference.
No measurements were reported for this outcome.
Difference in the 100-week change from baseline in Weight for height Z-score. Weight for height Z-scores are based on a reference growth chart (based on the growth charts from Centers for Disease Control and Prevention \[CDC\] for ages 0 to 20 years \[for ages 2 to \<12 years\]. A z-score of "0" represents the population mean. The Z-score indicates the number of standard deviations away from the mean of the reference population. A negative Z-score indicates values lower than the population mean while a positive Z-score indicates values higher than the population mean.
| z-score | Part C: Dupilumab |
|---|---|
| Part C: Change in Weight for Height Z-score From Baseline up to Week 100 | 0.3301 ± 0.84791 |
Weight for height z-score indicates how much higher or lower a participant's weight for height is relative to a reference growth chart (based on the growth charts from CDC for ages 0 to 20 years \[for ages 2 to \<12 years\] and WHO growth charts for ages 0 to \<2 years \[for ages 1 to \<2 years\]). An increase in the mean change in weight for height z-score (increase in the SD from the reference growth chart) indicates an increase in weight for height relative to the reference.
No measurements were reported for this outcome.
| Percentage of participants | Part C: Dupilumab |
|---|---|
| Part C: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eos/Hpf (400×) at Week 100 | 70.7 |
No measurements were reported for this outcome.
| Percentage of participants | Part C: Dupilumab |
|---|---|
| Part C: Percentage of Participants (With Food Elimination Diet Regimens at Baseline) That Have a Re-introduction of a Previously Eliminated Food Group From Baseline up to Week 100 | 14.8 |
No measurements were reported for this outcome.
| Participants | Part C: Dupilumab |
|---|---|
| Part C: Number of Participants With TEAEs | 53 |
| Participants | Part C: Dupilumab |
|---|---|
| Part C: Number of Participants With Treatment-emergent SAEs | 3 |
| Participants | Part C: Dupilumab |
|---|---|
| Part C: Number of Participants With Treatment-emergent AESIs | 6 |
| Participants | Part C: Dupilumab |
|---|---|
| Part C: Number of Participants With TEAEs Leading to Permanent Discontinuation of Study Treatment | 0 |
| Participants | Part C: Dupilumab |
|---|---|
| Part C: Number of Participants With Treatment-emergent ADA Responses | 0 |
| mg/L | Part C: Dupilumab |
|---|---|
| Part C: Concentration of Functional Dupilumab in Serum at Week 100 | 180 ± 96.9 |
Collected over From signing of the informed consent up to week 152.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Pooled Placebo (Placebo) | 0/34 (0%) | 0/34 (0%) | 28/34 (82.4%) |
| Part A: Dupilumab Low Dose | 0/30 (0%) | 0/30 (0%) | 24/30 (80%) |
| Part A: Dupilumab High Dose | 0/37 (0%) | 2/37 (5.4%) | 26/37 (70.3%) |
| Part B: Placebo to Dupilumab Low Dos | 0/14 (0%) | 1/14 (7.1%) | 14/14 (100%) |
| Part B: Placebo to Dupilumab High Dose | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| Part B: Dupilumab Low Dose to Dupilumab Low Dose | 0/29 (0%) | 2/29 (6.9%) | 27/29 (93.1%) |
| Part B: Dupilumab High Dose to Dupilumab High Dose | 0/37 (0%) | 2/37 (5.4%) | 31/37 (83.8%) |
| Part C: Dupilumab | 0/61 (0%) | 3/61 (4.9%) | 48/61 (78.7%) |
| Event | Part A: Pooled Placebo (Placebo) | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Part B: Placebo to Dupilumab Low Dos | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose | Part C: Dupilumab |
|---|---|---|---|---|---|---|---|---|
| LeukocytosisBlood and lymphatic system disorders | 0/34 | 0/30 | 0/37 | 1/14 | 0/18 | 0/29 | 0/37 | 0/61 |
| PyrexiaGeneral disorders | 0/34 | 0/30 | 0/37 | 1/14 | 0/18 | 0/29 | 0/37 | 0/61 |
| HCoV-OC43 infectionInfections and infestations | 0/34 | 0/30 | 0/37 | 0/14 | 0/18 | 1/29 | 0/37 | 0/61 |
| Throat tightnessRespiratory, thoracic and mediastinal disorders | 0/34 | 0/30 | 0/37 | 0/14 | 0/18 | 1/29 | 0/37 | 0/61 |
| Procedural painInjury, poisoning and procedural complications | 0/34 | 0/30 | 1/37 | 0/14 | 0/18 | 0/29 | 0/37 | 0/61 |
| NephrolithiasisRenal and urinary disorders | 0/34 | 0/30 | 1/37 | 0/14 | 0/18 | 0/29 | 0/37 | 0/61 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/34 | 0/30 | 0/37 | 0/14 | 0/18 | 0/29 | 1/37 | 0/61 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/34 | 0/30 | 0/37 | 0/14 | 0/18 | 0/29 | 1/37 | 0/61 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/34 | 0/30 | 0/37 | 0/14 | 0/18 | 0/29 | 1/37 | 0/61 |
| Obstructive sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/34 | 0/30 | 1/37 | 0/14 | 0/18 | 0/29 | 0/37 | 0/61 |
| Event | Part A: Pooled Placebo (Placebo) | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Part B: Placebo to Dupilumab Low Dos | Part B: Placebo to Dupilumab High Dose | Part B: Dupilumab Low Dose to Dupilumab Low Dose | Part B: Dupilumab High Dose to Dupilumab High Dose | Part C: Dupilumab |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/34 | 9/30 | 6/37 | 3/14 | 6/18 | 7/29 | 11/37 | 5/61 |
| Injection site reactionGeneral disorders | 7/34 | 4/30 | 4/37 | 4/14 | 5/18 | 4/29 | 5/37 | 5/61 |
| InfluenzaInfections and infestations | 0/34 | 0/30 | 1/37 | 4/14 | 1/18 | 4/29 | 4/37 | 3/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/34 | 2/30 | 1/37 | 1/14 | 5/18 | 4/29 | 5/37 | 8/61 |
| Upper respiratory tract infectionInfections and infestations | 3/34 | 1/30 | 0/37 | 2/14 | 1/18 | 8/29 | 2/37 | 8/61 |
| HeadacheNervous system disorders | 1/34 | 4/30 | 2/37 | 0/14 | 4/18 | 3/29 | 4/37 | 6/61 |
| PyrexiaGeneral disorders | 1/34 | 0/30 | 2/37 | 3/14 | 2/18 | 3/29 | 6/37 | 11/61 |
| Injection site painGeneral disorders | 0/34 | 3/30 | 0/37 | 3/14 | 1/18 | 1/29 | 1/37 | 3/61 |
| UrticariaSkin and subcutaneous tissue disorders | 2/34 | 2/30 | 1/37 | 3/14 | 0/18 | 2/29 | 1/37 | 2/61 |
| Pharyngitis streptococcalInfections and infestations | 0/34 | 0/30 | 0/37 | 2/14 | 1/18 | 2/29 | 0/37 | 13/61 |
Analysis was performed on Part A full analysis set (FAS) which included all randomized participants in Part A.
| Age, Continuous(years) | Part A: Pooled Placebo | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Total |
|---|---|---|---|---|
| Mean | 7.2 ± 3.03 | 7.2 ± 3.07 | 6.8 ± 3.11 | 7.1 ± 3.05 |
| Sex: Female, Male(Participants) | Part A: Pooled Placebo | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Total |
|---|---|---|---|---|
| Female | 9 | 6 | 9 | 24 |
| Male | 25 | 25 | 28 | 78 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Pooled Placebo | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 2 | 7 |
| Not Hispanic or Latino | 30 | 29 | 33 | 92 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Part A: Pooled Placebo | Part A: Dupilumab Low Dose | Part A: Dupilumab High Dose | Total |
|---|---|---|---|---|
| White | 30 | 22 | 32 | 84 |
| Black or African American | 3 | 4 | 4 | 11 |
| Asian | 0 | 1 | 1 | 2 |
| Other | 1 | 4 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Sep 2020 to primary completion in Jun 2022, 21 months.
Results were first posted in Aug 2024, 2 years 2 months after primary completion. A results delay was requested in Jun 2023.
Of 16 phase 3 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 37. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab